Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, announced an expanded partnership with Softek Illuminate, Inc., an industry leader in the development of proprietary natural language processing (NLP) and AI software that discovers at-risk patients from electronic medical records (EMR), assesses disease severity, and facilitates follow-up surveillance for a variety of diseases. This partnership will enable healthcare providers to make timely decisions for patients with cerebral aneurysms while ensuring patients are not lost to follow-up.
“An estimated 6.7 million people in the United States have an unruptured brain aneurysm. Through our collaboration with Illuminate, we have the opportunity to detect and monitor aneurysm more effectively by using AI-powered tools that prevent patients from falling through the cracks,” said Jieun Choe, Chief Product & Marketing Officer at Viz.ai. “We are confident this collaboration will help more patients get the continuity of care and treatment they need to reduce aneurysm rupture.”
Also Read: TME Pharma Teams with Aimed Analytics for AI Drug Discovery
According to the Brain Aneurysm Foundation, approximately 30,000 people in the U.S. suffer a brain aneurysm rupture each year, leading to serious health issues and, in 50% of cases, death. Viz Aneurysm™ leverages AI to automatically analyze computed tomography angiograms (CTAs) for suspected cerebral aneurysm and streamline referrals. Illuminate’s Discovery360 incorporates the people, process, and technology to identify and monitor lost aneurysm patients. After screening nearly 1,200 CTAs for stroke evaluation across eight stroke centers, Viz Aneurysm helped determine that 85% of aneurysms had not been previously referred to neurology for follow-up.1 Together, Viz Aneurysm and Illuminate’s Discovery360 equip care teams with the clinical insights they need to ensure timely diagnosis and patient follow-up.
“We are pleased to partner with Viz.ai to provide an end-to-end workflow, including follow-up surveillance and disease management, by combining our best-in-class technologies,” said Cole Erdmann, CEO of Illuminate. “This will ensure patients and physicians are able to make the best care decisions ultimately preventing ruptures.”
Source: Viz.ai
